EU agency calls for curbs on GSK, Valeant epilepsy drug

EU agency calls for curbs on GSK, Valeant epilepsy drug
LONDON (Reuters) - Use of an epilepsy drug developed by GlaxoSmithKline and Valeant Pharmaceuticals should be restricted to patients for whom other anti-epileptic medicines have proved inadequate or not tolerated, EU regulators said on Friday. The European Medicines Agency said the move followed cases of abnormal coloring of the skin, nails, lips and eye tissues, including the retina, in some patients who took Trobalt. It recommended a comprehensive eye examination should be performed at the start of treatment and at least every six months during treatment. ...